post-treatment Lyme disease syndrome

Summary

post-treatment Lyme disease syndrome (MONDO:0700280) is a disease and 8 clinical trials. Top therapeutic interventions include ceftriaxone. A subtype of post-bacterial disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	post-treatment Lyme disease syndrome
Mondo ID	MONDO:0700280
NCIT	C119039
UMLS	C3890422
MedGen	855646
Is cancer (heuristic)	no

Also known as: disorder due to consequences of Lyme disease · PLDS · post-Lyme disease · post-Lyme disease syndrome · post-treatment Lyme disease syndrome

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › post-infectious disorder › post-bacterial disorder › post-treatment Lyme disease syndrome

Related subtypes (1): rheumatic fever

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE1/PHASE2	3
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04141969	PHASE2/PHASE3	COMPLETED	A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome
NCT06511050	PHASE1/PHASE2	RECRUITING	Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
NCT04078841	PHASE1/PHASE2	COMPLETED	Treating Post-Lyme Disease Syndrome With Acetogenins
NCT06785402	PHASE1/PHASE2	WITHDRAWN	Ceftriaxone for Post-Treatment Lyme Disease
NCT04806620	Not specified	RECRUITING	Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
NCT06655844	Not specified	RECRUITING	Sana Device for Post-Treatment Lyme Disease Syndrome Chronic Pain
NCT02344537	Not specified	TERMINATED	Meditation and Stretching for Post Treatment Lyme Disease Syndrome
NCT04938687	Not specified	COMPLETED	Effect of Auricular Vagal Nerve Electrical Stimulation on Post-Treatment Lyme Disease Syndrome

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CEFTRIAXONE	4	1